- Home
- SBFM vs RVLV Comparison
SBFM vs RVLV Comparison
Compare SBFM & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- RVLV
- Stock Information
- Founded
- SBFM 2006
- RVLV 2003
- Country
- SBFM United States
- RVLV United States
- Employees
- SBFM N/A
- RVLV N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- RVLV Catalog/Specialty Distribution
- Sector
- SBFM Health Care
- RVLV Consumer Discretionary
- Exchange
- SBFM Nasdaq
- RVLV Nasdaq
- Market Cap
- SBFM 7.7M
- RVLV N/A
- IPO Year
- SBFM N/A
- RVLV 2019
- Fundamental
- Price
- SBFM $1.45
- RVLV $20.17
- Analyst Decision
- SBFM Strong Buy
- RVLV Buy
- Analyst Count
- SBFM 1
- RVLV 15
- Target Price
- SBFM $15.00
- RVLV $26.20
- AVG Volume (30 Days)
- SBFM 84.3K
- RVLV 1.3M
- Earning Date
- SBFM 08-15-2025
- RVLV 08-05-2025
- Dividend Yield
- SBFM N/A
- RVLV N/A
- EPS Growth
- SBFM N/A
- RVLV 106.68
- EPS
- SBFM N/A
- RVLV 0.71
- Revenue
- SBFM $36,234,578.00
- RVLV $1,156,039,000.00
- Revenue This Year
- SBFM $192.48
- RVLV $7.71
- Revenue Next Year
- SBFM N/A
- RVLV $7.64
- P/E Ratio
- SBFM N/A
- RVLV $28.41
- Revenue Growth
- SBFM 35.51
- RVLV 9.09
- 52 Week Low
- SBFM $1.17
- RVLV $14.88
- 52 Week High
- SBFM $8.78
- RVLV $39.58
- Technical
- Relative Strength Index (RSI)
- SBFM 48.48
- RVLV 46.23
- Support Level
- SBFM $1.41
- RVLV $19.60
- Resistance Level
- SBFM $1.58
- RVLV $20.89
- Average True Range (ATR)
- SBFM 0.12
- RVLV 0.86
- MACD
- SBFM -0.01
- RVLV -0.14
- Stochastic Oscillator
- SBFM 18.91
- RVLV 19.01
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.